Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Extended half-life“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Extended half-life" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Extended half-life"
Kontermann, Roland E. „Half-life extended biotherapeutics“. Expert Opinion on Biological Therapy 16, Nr. 7 (18.04.2016): 903–15. http://dx.doi.org/10.1517/14712598.2016.1165661.
Der volle Inhalt der QuelleFUJII, Teruhisa. „Extended half life coagulation products for hemophilia“. Japanese Journal of Thrombosis and Hemostasis 28, Nr. 4 (2017): 472–79. http://dx.doi.org/10.2491/jjsth.28.472.
Der volle Inhalt der QuellePadhi, Desmond, Liyun Ni, Blaire Cooke, Rafael Marino und Graham Jang. „An Extended Terminal Half-Life for Darbepoetin Alfa“. Clinical Pharmacokinetics 45, Nr. 5 (2006): 503–10. http://dx.doi.org/10.2165/00003088-200645050-00005.
Der volle Inhalt der QuelleMorfini, Massimo. „A new, promising, extended half-life rFIX concentrate“. Lancet Haematology 4, Nr. 2 (Februar 2017): e59-e60. http://dx.doi.org/10.1016/s2352-3026(17)30003-0.
Der volle Inhalt der QuelleNesspor, Thomas C., und Bernard Scallon. „Chimeric antibodies with extended half‐life in ferrets“. Influenza and Other Respiratory Viruses 8, Nr. 5 (30.07.2014): 596–604. http://dx.doi.org/10.1111/irv.12273.
Der volle Inhalt der QuelleCroteau, S. E., und E. J. Neufeld. „Transition considerations for extended half-life factor products“. Haemophilia 21, Nr. 3 (09.04.2015): 285–88. http://dx.doi.org/10.1111/hae.12683.
Der volle Inhalt der QuelleGraf, Lukas. „Extended Half-Life Factor VIII and Factor IX Preparations“. Transfusion Medicine and Hemotherapy 45, Nr. 2 (2018): 86–91. http://dx.doi.org/10.1159/000488060.
Der volle Inhalt der QuelleKontermann, Roland E. „Strategies for extended serum half-life of protein therapeutics“. Current Opinion in Biotechnology 22, Nr. 6 (Dezember 2011): 868–76. http://dx.doi.org/10.1016/j.copbio.2011.06.012.
Der volle Inhalt der QuelleTortella, Bartholomew J., José Alvir, Margaret McDonald, Dean Spurden, Patrick F. Fogarty, Amit Chhabra und Andreas M. Pleil. „Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products“. Journal of Managed Care & Specialty Pharmacy 24, Nr. 7 (Juli 2018): 643–53. http://dx.doi.org/10.18553/jmcp.2018.17212.
Der volle Inhalt der QuelleGEHRING, R., R. E. BAYNES, A. L. CRAIGMILL und J. E. RIVIERE. „Feasibility of Using Half-Life Multipliers To Estimate Extended Withdrawal Intervals following the Extralabel Use of Drugs in Food-Producing Animals“. Journal of Food Protection 67, Nr. 3 (01.03.2004): 555–60. http://dx.doi.org/10.4315/0362-028x-67.3.555.
Der volle Inhalt der QuelleDissertationen zum Thema "Extended half-life"
Zhu, Eric F. (Eric Franklin). „Synergistic anti-tumor immune response to combination immunotherapy consisting of anti-tumor antibodies, extended half-life Interleukin-2, and other immunomodulatory agents“. Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/107872.
Der volle Inhalt der QuelleCataloged from PDF version of thesis.
Includes bibliographical references (pages 109-123).
Cancer immunotherapies under development have generally focused on either stimulating T-cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). However, as our understanding of antitumor immune responses grows, it has become increasingly apparent that single agent therapies may be insufficient to effectively stimulate all aspects of a complex robust anti-tumor response in a large proportion of patients. Thus, rational combination of single agent immunotherapies has become an area of increasing interest. In this work, we find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response. We find that this therapy induces the infiltration of various immune effectors such as neutrophils, eosinophils NK cells, and CD8+ T-cells that appear to direct cytolytic activity against tumor cells. This combination therapy also induces an intratumoral "cytokine storm," potentially re-polarizing the tumor microenvironment into one that is immunologically anti-tumor. We also identify cross-talk between NK cells and macrophages to induce intratumoral recruitment of neutrophils but with the requisite presence of anti-tumor antibodies and IL-2 simultaneously. We further enhanced the efficacy of this two-component therapy with the addition of a potent amphiphile-based anti-tumor peptide vaccine in combination with checkpoint blockade of anti-PD-I and anti-CTLA-4. This multi-component therapy was tested in a setting of a low-mutational burden GEM lung cancer model with a single known and targetable antigen: human carcinoembryonic antigen (CEA). We find that in the subcutaneous setting and autochthonous setting, both components of checkpoint blockade are necessary for full efficacy. While a 5- component therapy is admittedly unwieldy for clinical translation, understanding the complementary yet non-overlapping contributions of each agent may inform improved development of additional immunotherapy agents and their combinations in the clinic.
by Eric F. Zhu.
Ph. D.
Desage, Stéphanie. „Facteurs VIII et IX humains recombinants à demi-vie prolongée pour le traitement de l’hémophilie A et B“. Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10305.
Der volle Inhalt der QuelleHaemophilia is a rare inherited bleeding disorder caused by a deficiency in clotting factors: factor VIII (FVIII) in haemophilia A and factor IX (FIX) in haemophilia B. The severity of the condition is determined by the plasma activity levels of FVIII or FIX. Patients with severe haemophilia typically have FVIII or FIX levels below 1 IU/dL, leading to spontaneous bleeding episodes that require prophylactic treatment. Since the 2010s, extended half-life coagulation factors have been developed to reduce the frequency of intravenous infusions and enhance patients' quality of life. In the first phase of our study, we explored the mechanisms responsible for the extended half-life of a FIX fused to the Factor XIII B subunit (FXIIIB). Our findings demonstrated that the extended half-life of this molecule is attributed to its ability to bind to fibrinogen and albumin. In the second phase of our study, we attempted to develop an extended half-life FVIII by fusing it with FXIIIB. However, due to the large size of the construct, no functional FVIII could be successfully produced. The third part of our research focused on the clinical use of efmoroctocog alfa, as more real-world data is needed on its application. Our results show that the use of a chromogenic FVIII assay to assess plasma FVIII activity during surgery provides more accurate results that correlate with clinical outcomes, we also confirmed in real life conditions that the use of efmoroctocog alfa is effective, safe and well tolerated
Bücher zum Thema "Extended half-life"
Silveira, Maria J., und Phillip Rodgers. Advance directives and advance care planning. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780198802136.003.0020.
Der volle Inhalt der QuelleRowe, Anne. Iris Murdoch. Liverpool University Press, 2019. http://dx.doi.org/10.3828/liverpool/9780746312162.001.0001.
Der volle Inhalt der QuelleMitchell, Lee Clark. More Time. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198839224.001.0001.
Der volle Inhalt der QuelleGrass, Tim. Restorationists and New Movements. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780199683710.003.0007.
Der volle Inhalt der QuelleBuchteile zum Thema "Extended half-life"
Abraham, Sunil, und Elizabeth M. Duncan. „A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B“. In Methods in Molecular Biology, 569–88. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3175-1_37.
Der volle Inhalt der QuelleGüngör, Bengü. „Circular Economy Business Model Framework Considering Product Sustainability“. In Creating a Roadmap Towards Circularity in the Built Environment, 305–15. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-45980-1_25.
Der volle Inhalt der QuelleReimers, Fernando M., und Francisco Marmolejo. „Leading Learning During a Time of Crisis. Higher Education Responses to the Global Pandemic of 2020“. In Knowledge Studies in Higher Education, 1–41. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-82159-3_1.
Der volle Inhalt der QuelleIngram, David. „9. Creating and Sustaining the Care Information Utility“. In Health Care in the Information Society, 395–526. Cambridge, UK: Open Book Publishers, 2023. http://dx.doi.org/10.11647/obp.0384.05.
Der volle Inhalt der QuelleSnyder, Sherri. „One“. In Barbara La Marr. University Press of Kentucky, 2017. http://dx.doi.org/10.5810/kentucky/9780813174259.003.0002.
Der volle Inhalt der QuelleDowling, Álvaro, und Kai-Uwe Lewandrowski. „The Implications of Low Back Pain on Prolonged Lifespan and Future Targeted Care Models to Support the Pursuit of Healthy Longevity“. In Regenerative Medicine & Peripheral Nerve Endoscopy, 1–15. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815274462124010003.
Der volle Inhalt der QuelleJunior, Nyasha, und Jeremy Schipper. „Samson and the Making of American Martyrs“. In Black Samson, 35–48. Oxford University Press, 2020. http://dx.doi.org/10.1093/oso/9780190689780.003.0004.
Der volle Inhalt der QuelleFennell, Jack. „The Undead Generations“. In Rough Beasts, 158–85. Liverpool University Press, 2020. http://dx.doi.org/10.3828/liverpool/9781789620344.003.0007.
Der volle Inhalt der QuelleJoseph, Jipson, und Ananya Pandey. „Right-Based Approach to Reproductive Autonomy“. In Advances in Public Policy and Administration, 185–208. IGI Global, 2024. http://dx.doi.org/10.4018/979-8-3693-7837-3.ch007.
Der volle Inhalt der QuelleEhrenreich, Andreas. „Horváth, Ödön von (Edmund Josef von Horváth) (1901–1938)“. In Routledge Encyclopedia of Modernism. London: Routledge, 2024. http://dx.doi.org/10.4324/9780415249126-rem2151-1.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Extended half-life"
Li, Xiaofan, Cristina Abrahams, Amandeep Gakhal, Junhao Yang, Kevin Brar, Daniel Calarese, Robert Henningsen et al. „1359 Half-life extended engineered IL18 variants that escape the negative regulation of IL18BP“. In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1359.
Der volle Inhalt der QuelleBasran, Amrik, Emma Jenkins, Estelle Adam, Floriane Laurent, Michele Writer, Assa Oumie, Jyrki Sivula et al. „Abstract 4108: Preclinical evaluation of half-life extended Affimer® biotherapeutics targeting the PD-L1 pathway“. In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4108.
Der volle Inhalt der QuelleBasran, Amrik, Emma Jenkins, Estelle Adam, Floriane Laurent, Michele Writer, Assa Oumie, Jyrki Sivula et al. „Abstract 4108: Preclinical evaluation of half-life extended Affimer® biotherapeutics targeting the PD-L1 pathway“. In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4108.
Der volle Inhalt der QuelleYam, Alice, Kshama Doshi, Krishna Bajjuri, Millicent Embry, Frank Xiao, Grace Lee, Stephanie Armstrong et al. „1103 Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response“. In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1103.
Der volle Inhalt der QuelleYu, chunxiao, Kurt Shanebeck, Shiwen Zhang, Jeanine Ruiz, Ray Chuang, Yuanxia Yuan, Yong Wen et al. „Abstract 1742: Activatable Fc-IL-15 and anti-PD1 -IL-15 fusion molecules with extended half-life“. In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1742.
Der volle Inhalt der QuelleDigiandomenico, A., A. Dippel, R. Varkey, A. Lidwell, L. Zhuang, V. Godfrey, Z. Bhuiyan et al. „Identification of a New IgG mAb Format with Enhanced Complement Mediated Effector Function and Extended Half Life“. In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4648.
Der volle Inhalt der QuelleKristensen, Jens Bjelke, Lisbeth Elster, Morten Lundh, Borja Ballarín-González, Flora Alexopoulou, Martin Kræmer, Ditte Marie Jensen et al. „Pipeline for development of acylated peptide-based CGRP receptor antagonist with extended half-life for migraine treatment“. In 37th European Peptide Symposium, 2200. The European Peptide Society, 2024. http://dx.doi.org/10.17952/37eps.2024.p2200.
Der volle Inhalt der QuelleArvedson, Tara L., Mercedesz Balazs, Pamela Bogner, Kurt Black, Kevin Graham, Anja Henn, Matthias Friedrich et al. „Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing“. In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-55.
Der volle Inhalt der QuelleLemon, Bryan, Wade Aaron, Richard Austin, Patrick Baeuerle, Manasi Barath, Adrie Jones, Susan D. Jones et al. „Abstract 1773: HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer“. In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1773.
Der volle Inhalt der QuelleMiebach, G., S. Juranek, V. Lieftüchter, C. Bidlingmaier und M. Olivieri. „Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A“. In GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0042-1760547.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Extended half-life"
De Paiva Abreu, Marcelo. The Political Economy of High Protection in Brazil before 1987. Inter-American Development Bank, April 2004. http://dx.doi.org/10.18235/0011099.
Der volle Inhalt der Quelle